Amir Tamiz

Dr. Tamiz is the Director of the Division of Translational Research (DTR) at the National Institute of Neurological Disorders and Stroke (NINDS). DTR provides funding and resources (approximately $200 million annually) through grants, cooperative agreements, and contracts to academic and industry researchers to advance early-stage neurological technologies, devices, and therapeutic programs to industry adoption (i.e., investor funding and corporate partnerships). Dr. Tamiz has oversight for many flagship programs within NINDS/NIH including the NIH Blueprint Neurotherapeutics Network (BPN) and Blueprint MedTech programs, NIH Helping to End Addiction Long-term (HEAL) Preclinical Screening Platform (PSPP) and Pain Therapeutics Development Program (PTDP), NINDS Small Business Program, Office of Neural Exposome and Toxicology (ONETOX), NINDS Biomarker Program, Innovation Grants to Nurture Initial Translational Efforts (IGNITE), and NINDS Epilepsy Therapy Screening Program (ETSP). Prior to that he was a program director overseeing BPN and IGNITE. Prior to joining NIH in 2012, Dr. Tamiz had held scientific and management positions in research and development of therapeutic programs at Corvas International (acquired by Dendreon), CovX (now part of Pfizer), and Alba Therapeutics.